glp 1 effects on liver Therapeutic Mechanisms and Clinical of Glucagon-like Peptide Receptor Agonists in Nonalcoholic Fatty Disease A Comprehensive Review of the

5 BaeC.SongJ

PMID 24003936

In a clinical trial of more than 3,000 adults with obesity, participants who received the highest dose of orforglipron, 36 milligrams, lost 11.2% of their body weight -- about 25 pounds on average -- over more than 16 months

Combination therapies Newer combination treatments like CagriSema (cagrilintide plus semaglutide) are being studied as weekly injections

Both medications are effective GLP-1-based therapies

People taking multiple medications alongside semaglutide should discuss potential interactions with their prescriber, particularly if they notice new sensory symptoms after adding or changing other medications